Co-Authors
This is a "connection" page, showing publications co-authored by MASATAKA SUZUKI and AMANDA ROSEWELL SHAW.
Connection Strength
4.560
-
HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy. Cancers (Basel). 2022 Jun 02; 14(11).
Score: 0.878
-
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 03 19; 4(1):368.
Score: 0.807
-
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment. Front Immunol. 2018; 9:2103.
Score: 0.679
-
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451.
Score: 0.633
-
Recent advances in oncolytic adenovirus therapies for cancer. Curr Opin Virol. 2016 12; 21:9-15.
Score: 0.582
-
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.
Score: 0.232
-
Current development in adenoviral vectors for cancer immunotherapy. Mol Ther Oncolytics. 2021 Dec 17; 23:571-581.
Score: 0.212
-
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Mol Ther. 2021 02 03; 29(2):505-520.
Score: 0.197
-
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262.
Score: 0.187
-
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
Score: 0.152